• Даминова Л.Т., Абдашимов З.Б.
  Ташкентский государственный стоматологический институт, Республика Узбекистан, г. Ташкент

Abstract

Нестероидные противовоспалительные препараты (НПВП) - это группа широко используемых лекарств. Важной проблемой при приеме НПВП являются побочные реакции со стороны желудочно-кишечного тракта (ЖКТ) на различных уровнях - от диспепсии до опасных для жизни осложнений, таких как кровотечение или перфорация раны. Вышеизложенные слова подтверждают, что данная статья является актуальной на сегодняшний день.

Keywords

НПВП, желудочно-кишечный тракт, диспепсия, кро-вотечение, механизм.

Literature

Klyaritskaya I.L., Rabotyagova Yu.S. CYP2C19 gen polimorfizmi va uning ta'rifining klinik ahamiyati. Qrim terapevtik jurnali 2013; 1: 19-25.

2. "Klinik amaliyotda steroid bo'lmagan yallig'lanishga qarshi dorilarni (NSAID) oqilona qo'llash" klinik ko'rsatmalari. Zamonaviy revmatologiya. 2015; 1: 4-23.

3. Obzherina A.Yu., Sychev DA, Muravyova Yu.V., Ignatiev IV, Dmitriev VA, Kukes VT CYP2C9 polimorfizmi: steroid bo'lmagan yallig'lanishga qarshi preparatlarni qo'llash bilan oshqozon-ichak traktining asoratlari rivojlanishi uchun yangi xavf omili. Klinik farmakologiya va farmakoiqtisodiyot. 2009; 2 (5): 20-5.

Blanco G., Martínez C., Ladero J.M. Interaction of CYP2C8 and CYP2C9 genotypes modifies the risk for nonsteroidal anti-inflammatory drugs-related acute gastrointestinal bleeding. // Pharmacogenet Genomics. – 2008. - vol.18(1). – P. 37–43.

Carbonell N., Verstuyft C., Massard J. CYP2C9*3 Loss-of-Function Allele Is Associated With Acute Upper Gastrointestinal Bleeding Related to the Use of NSAIDs Other Than Aspirin // Clin. Pharmacol. Ther. – 2010. - vol.87(6). – P. 693–698.

Denisenko NP, Sychev DA, Sizova ZM, et al. Urine metabolic ratio of omeprazole in relation to CYP2C19 polymorphisms in Russian peptic ulcer patients. Pharmgenomics Pers Med. 2017;10:253–259. DOI: 10.2147/PGPM.S141935

Estany-Gestal A., Salgado-Barreira A., Sánchez-Diz P., Figueiras A. Influence of CYP2C9 genetic variants on gastrointestinal bleeding associated with nonsteroidal anti-inflammatory drugs: a systematic critical review. // Pharmacogenet. Genomics. – 2011. -vol. 21(7). – P. 357–364.

Furuta T, Sugimoto M, Shirai N. Individualized therapy for gastroesophageal reflux disease: potential impact of pharmacogenetic testing based on CYP2C19. Mol Diagn Ther. 2012;16(4):223–234. DOI: 10.2165/11634960-000000000-00000

Hunfeld N.G., Mathot R.A., Touw D.J. Effect of CYP2C19*2 and *17 mutations on pharmacodynamics and kinetics of proton pump inhibitors in Caucasians // Br. J. Clin. Pharmacol. – 2008. – vol. 65(5). – P. 752–760.

Hunt R.H., Lanas A., Stichtenoth D.O., Scarpignato C. Myths and facts in the use of anti-inflammatory drugs //Ann. Med. – 2009. - Vol. 41(6). – P. 423–437.

Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers Baldwin R.M., Ohlsson S., Pedersen R.S. et al. //Br. J. Clin. Pharmacol. – 2008. – vol. 65(5). – P. 767–774.

Ingelman-Sundberg M., Sim S.C., Gomez A., Rodriguez-Antona C. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects // Pharmacol. Ther. – 2007. – vol.116(3). – P. 496–526.

Kaspera R., Totah R.A. Epoxyeicosatrienoic acids: formation, metabolism and potential role in tissue physiology and pathophysiology // Expert Opin. Drug Metab. Toxicol. – 2009. – vol.5(7). – P. 757–771.

Li-Wan-Po A., Girard T., Farndon P. Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17. // Br. J. Clin. Pharmacol. – 2010. – vol. 69(3): 222–230.

Ma J., Yang X.Y., Qiao L. CYP2C9 polymorphism in non-steroidal anti-inflammatory drugs-induced gastropathy // J. Dig. Dis. – 2008. – vol. 9(2): 79–83.

Martínez C, Blanco G, Ladero JM, et al. Genetic predisposition to acute gastrointestinal bleeding after NSAIDs use. Br J Pharmacol. 2004;141(2): 205–208. DOI: 10.1038/sj.bjp.0705623

Musumba C.O., Jorgensen A., Sutton L. et al. (2013) CYP2C19*17 gain-of-function polymorphism is associated with peptic ulcer disease // Clin. Pharmacol. Ther. 2013. - 93(2): 195–203.

Pedersen R.S., Brasch-Andersen C., Sim S.C. Linkage disequilibrium between the CYP2C19*17 allele and wildtype CYP2C8 and CYP2C9 alleles: identification of CYP2C haplotypes in healthy Nordic populations // Eur. J. Clin. Pharmacol. – 2010. – vol. 66(12): 1199–1205.

Pilotto A, Seripa D, Franceschi M, et al. Genetic susceptibility to nonsteroidal anti-inflammatory drug-related gastroduodenal bleeding: role of cytochrome P450 2C9 polymorphisms. Gastroenterology. 2007;133(2):465–471.

Preissner SC, Hoffmann MF, Preissner R Polymorphic cytochrome P450 enzymes (CYPs) and their role in personalized therapy // PLoS One 2013;8(12): e82562.

Scott S.A., Martis S., Peter I. et al. Identification of CYP2C19*4B: pharmacogenetic implications for drug metabolism including clopidogrel responsiveness // Pharmacogenomics J. – 2012. – vol. 12(4): 297–305.

Vogl S, Lutz RW, Schönfelder G, Lutz WK. CYP2C9 genotype vs. metabolic phenotype for individual drug dosing--a correlation analysis using flurbiprofen as probe drug. PLoS One. 2015 Mar 16;10(3):e0120403. DOI: 10.1371/journal.pone.0120403